Alexion’s Soliris gets new, and lucrative, rare disease indication

Alexion’s rare disease drug Soliris has a new indication after the FDA approved it for a disease that attacks the optic nerves. Approval of Soliris (eculizumab) for neuromyelitis optica spectrum disorder (NMOSD) in adults who have the anti-aquaporin-4 antibody opens up further revenues for Alexion, which has already built a blockbuster franchise around the drug.
Read more...

;